Funding for this research was provided by:
RCUK | Medical Research Council (MR/N025989/1)
DH | National Institute for Health Research (Oxford BRC)
Received: 14 December 2020
Revised: 13 January 2021
Accepted: 3 February 2021
First Online: 15 March 2021
Ethics approval and consent to participate
: Ethical approval for sample collation and record analysis was performed within the Oxford Radcliffe Biobank (09/H0606/5 + 5) was granted through applications: OCHRe 16/A019, 18/A064. Samples from the Clatterbridge Cancer Centre approval was approved for the HYST study: 12/NW/0525, local approval 17–18/40.
: Sequencing data deposited at European Genome–phenome Archive under accession no. ExternalRef removed, available via a data access agreement.
: M.R.M. reports personal fees from Amgen, grants and personal fees from Roche, grants from Astrazeneca, grants and personal fees from GSK, personal fees and other from Novartis, other from Millenium, personal fees, non-financial support and other from Immunocore, personal fees and other from BMS, personal fees and other from Eisai, other from Pfizer, personal fees, non-financial support and other from Merck/MSD, personal fees and other from Rigontec (acquired by MSD), other from Regeneron, personal fees from BiolineRx, personal fees and other from Array Biopharma (now Pfizer), non-financial support and other from Replimune, outside the submitted work. M.P. has received support with conference travel, and fees for advisory work and speaking from Amgen, BMS, L’Oreal, MSD, Novartis and Pierre Fabre. BPF received support with conference travel from BMS. All other authors report no competing interests.
: This work was supported by National Institute for Health Research (NIHR) Oxford Biomedical Research Centre (BRC). The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health. B.P.F. is Wellcome funded (201488/Z/16/Z). A.C.O.B. is MRC funded (MR/N025989/1).